San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug market place in February just after revealing promising details from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented being a weekly injection As well as